In:
International Journal of Cancer, Wiley, Vol. 136, No. 7 ( 2015-04), p. 1537-1545
Abstract:
What's new? The monoclonal antibody trastuzumab is effective against HER2‐positive gastric cancers (GCs). However, as with breast cancer, many GCs develop resistance to this drug. In this study, the authors found that a microRNA called “miR‐233” interacts with a gene called “FBXW7” to regulate the sensitivity of HER2‐positive GC cells to trastuzumab, by altering apoptosis. These results suggest that the miR‐223/FBXW7 pathway may be a valuable therapeutic target to decrease resistance of GC to trastuzumab.
Type of Medium:
Online Resource
ISSN:
0020-7136
,
1097-0215
Language:
English
Publisher:
Wiley
Publication Date:
2015
detail.hit.zdb_id:
218257-9
detail.hit.zdb_id:
1474822-8
Permalink